Ovarian Cancer
News and reporting on ovarian cancer.
The firm has commercialized its pancreatic cancer test and has its sights set on an ovarian cancer test launching in 2023.
Roche Nabs FDA Approval for Ventana Test as CDx for Elahere
The immunohistochemistry-based test detects the folate receptor 1 protein that is over-expressed in most ovarian cancers.
The firm cited new study results confirming that an assay analyzing circulating tumor cells isolated by its Parsortix platform can discriminate malignant pelvic masses.
AOA Dx Closes $7M Funding Round for Ovarian Cancer Test
The firm will use the money to develop its technology for detecting biomarkers of early-stage ovarian cancer through tumor marker gangliosides.
The company plans to launch a commercial product sometime after completing its currently ongoing Series A funding round.
May 11, 2022
May 14, 2021